Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in persons living with human immunodeficiency virus (HIV), for the prevention of pneumococcal disease caused by the serotypes in the vaccine.
Epistemonikos ID: 6a4835ece8f4da30427d544ef3e77dfca687eecb
First added on: May 13, 2024